We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Loads….yet you sold shares last, as you (claimed) you did when it was. >18p
What’s your average here EC?
One wonders what others are in the pipeline.
There are thousands of Pharma Co's IN THE WORLD. Food for thought TwoGood2Die, is it not!!! LOL!
I think there will be LOADS in the next 4 months. LOADS.
All IMHO.
The Board really should demand that Newland’s salary be cut back as he persists in misleading investors. Outrageous that he was allowed to stick his finger in the air and guess at a tripling of revenues and then provide absolutely no solid reasoning as to why.
Nearly half the year gone and no sign of the £6m in order to extend the cash runway to Q2 next year.
It was around this time last year that the last cash placement was raised!
Miavoce
Revenue is cash at the end of the day is it not?
The company have confirmed there’s a funding gap. It would be very optimistic to think that since Novembers trading update we’ve not only found the trebling £6m of revenue, but surpassed that to such an extent that we’ve extended the runway. We are indeed speculating about the performance this year but there’s no RNS to point to around material revenue. I suspect we won’t hit the £6m and thus the runway is shorter.
Hi TGTD, it is incorrect to say that the company needs a minimum of 12 months cash to meet going concern requirements for the auditor's to sign off the 2023 accounts in May. There is no such requirement for a going concern status.
What Angle need to be able to demonstrate is that either their revenue + cash will be sufficient to keep the company operating, or that their revenue + cash + a feasible cash raise (if necessary) will be sufficient.
Whether / when a cash raise is needed will become much clearer when we get some current trading / outlook info with the imminent results publication. Until then everything is pure speculation.
When is the next cash placement andvat what price...🤔
It's now getting pretty obvious that the additional £6m of revenues that Newland spouted finger wagging style in order to extend the cash run way till Q2 2025 are not going to materlise soon.
We now have RNS's proclaiming success stories but when you look for the financials they are just tiny miniscule amounts.
It seems these are designed solely to prop up the share price ahead of an imminent cash placement imho.
With cash dwindling to around £7m or £8m its about now thar news on a fund raise would be expected as you need a minimum of 12 months cash to meet going concern requirements for the auditor's to sign off the 2023 accounts in May.
It's already noted in the RNS on the 22nd :
"We are delighted to have secured intellectual property rights for our proprietary CellKeep slide in two major jurisdictions."
Hopefully more news next week. Well suppressed by mms. Better days next week. Gla
Angle now have both Eisia In. (top 100 Japanese Co) and Astrazeneca (FTSE 100 Co.) on their books.
Acorns grow to oak trees............
Where did you get the $232 billion from! Thin air?
Almost all buys but price flat
IMHO the sp should be 18p+, absolute minimum. The bottom line is the Parsortix machine did not sell as well as they had hoped after FDA clearance. The problem was Angle hoped/expected the Pharma clients to do the work needed after the Parsortix machine had caught the circulating tumour cells to test. Also, this is such "cutting edge technology" that some labs simply did not have the technical knowhow to do the assays. Angle have now have a HER2 assay, a PD-L1 assay, a portrait flex assay, and a DNA Damage Response one. Also, the Portrait+ CTC kit which makes using the machine easier and standardises the stains used. These are now driving the Services side of the business which demonstrate the results the Parsortix machine can deliver, and no doubt increases sales of the Parsortix machine.
8th Apr 2024 7:00 am RNS Parsortix HER2 assay showcased at AACR 2024
https://www.lse.co.uk/rns/AGL/parsortix-her2-assay-showcased-at-aacr-2024-4k393y7ivsvtwno.html
5th Dec 2023 7:00 am RNS ANGLE launches Portrait+ CTC kit at SABCS
https://www.lse.co.uk/rns/AGL/angle-launches-portrait-ctc-kit-at-sabcs-5mzhyiaiggmk83j.html
9th Nov 2023 7:00 am RNS Launch of PD-L1 test to support cancer studies
https://www.lse.co.uk/rns/AGL/launch-of-pd-l1-test-to-support-cancer-studies-o8m4cvtjt6ft9a9.html
4th Sep 2023 7:00 am RNS ANGLE launch of Portrait Flex assay
https://www.lse.co.uk/rns/AGL/angle-launch-of-portrait-flex-assay-q8vjkxoz5ew8ywd.html
25th May 2023 7:00 am RNS Pharma services contract with Artios Pharma
https://www.lse.co.uk/rns/AGL/pharma-services-contract-with-artios-pharma-mjim4s7jtk1clj5.html
All IMHO
Last Trading Update
Revenue recognised for 2024 is expected to treble compared to 2023 with the growth of distributor sales, and with the planned launches of the Portrait PD-L1 test (services), see separate announcement today, the Portrait+ antibody staining kit (products), and the Parsortix BiDetectTM DNA solutions combining ctDNA and CTC-DNA analysis (products and services) all contributing to the Company's sales growth ambitions.
Business update - Streamlining services business extends cash runway
With the expected growth in molecular solutions requiring investment and considering ongoing adverse market conditions, we have made the decision to streamline our Services operations by closing the US clinical laboratory and focusing on a single UK-based centre of excellence. We have developed solutions for sample stability so that the physical location of the laboratory does not limit its capability to service customers across different geographies. The streamlining will enable us to focus our investment in multiple molecular platforms for different applications in a single location without duplicating these significant costs.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"The build-up of revenues has been slower than hoped but is moving in the right direction and the Company expects strong revenue growth year-on-year. The cost savings from the streamlining of our clinical services business will now extend the forecast cash runway into Q2 2025 and we look forward to progressing the planned launches of new products and services to drive widespread adoption of the Company's Parsortix system to support precision medicine in cancer."
Berenberg Bank reaffirmed their buy rating on shares of ANGLE (LON:AGL – Free Report) in a research report released on Wednesday morning, Marketbeat Ratings reports. The brokerage currently has a GBX 70 ($0.86) target price on the stock
The Uk market is a sad state of affairs overall right now as is the fact the Uk seen as a basket case for investing by many.
Even UK pension funds had to face lobbying to persuade them to invest in UK equities.
I saw a doc on bbc called Inside story about the UK market in the 1970’s. Even back then the markets raised 600 million for new issues in 6 months.
Whats the UK market had in last 12 months?, crappy floats like CAB which was valued at a billion on wafer thin FX margins and it tanked as expected while the good stuff like ARM opted not to re-list in London.
Sad state of overall affairs.
The current sp, which I don't think anyone disagrees is very depressed, is a feature of a fear that the Company will need to do a fundraising in order to extend their Q2 '25 cash runway to get to cash flow break-even.
Investors in other healthcare stocks have been burned before by deeply discounted placings and recently there's been a number or listing cancellations from peers of ANGLE that ran out of money including the likes or RedX, ReNeuron etc
On a factual basis this isn't a like-for-like situation, why, well quite simply:
Who were the advisors/brokers on those other stocks? Small-cap commission driven houses. ANGLE has a grown up Mid-Cap broker
How many of those stocks had contracts with AstraZeneca? None
ANGLE were at 30p+ in Jan, they could have raised money then with ease if they wanted to, they didn't. So clearly they have plenty of optionality and are not panicking
They are now in-play with both EISAI and AstraZeneca where the end demand for their $1000+ kits which are required 2 or 3 times per patient will be needed for 10's of thousands of patients (do the maths)
The Company could walk into a top-tier finance house today with the credentials of EISAI and AstraZeneca and get a Rolling Credit Facility if they really wanted to, they don't have to come to equity markets if they feel their valuation isn't being truly reflected
So whilst investors are referring to the pain of previous experiences it really isn't relevant here
Finally I think its very sad that a small British quoted company like ANGLE which has an FDA approved cancer detection product being put to use by 2 global Pharma companies has people shunning it for its cash position as if it were some pie in the sky early stage niche drug development company
Nothing wrong with hedging your bets
TwoGood2Die
So says the Carrot day trader trying to pretend he is a LTH lol!
Caught our red handed ✋️ 😳 lol
==================================
I am a long term holder! Why do you think I post here almost every day?
I think you need to be sedated and locked in room that has rubber wallpaper.
https://www.youtube.com/watch?v=TPvD_nmu4W8
Carot you are the one endlessly copy and pasting this BB with any irrelevant nonsense you can find on the Internet...How many times can one person spam the BB...
Your a day trader we get it so stop trying to pretend you have the company's long term interests at heart you just want to make a fast buck and vanish!
I have never "slipped up and gave the game away by 'inadvertently' posting on this BB that you were a day trader dumping stock.". Total lie! Got me confused with someone else, or just made it up? ****Do you have mental issues?****.
.........LOL Really?
So says the Carrot day trader trying to pretend he is a LTH lol!
Caught our red handed ✋️ 😳 lol
TwoGood2Die.
"Rampety ramp ramp....!"
============================
I think you need the men in white coats and a van to get you diagnosed and possibly sectioned under the mental health act. By the way you forgot the link:-
https://www.youtube.com/watch?v=TPvD_nmu4W8
Rampety ramp ramp....!